Cannara Biotech Past Earnings Performance

Past criteria checks 2/6

Cannara Biotech has been growing earnings at an average annual rate of 74.5%, while the Personal Products industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 59% per year. Cannara Biotech's return on equity is 6.5%, and it has net margins of 6.9%.

Key information

74.5%

Earnings growth rate

75.2%

EPS growth rate

Personal Products Industry Growth35.8%
Revenue growth rate59.0%
Return on equity6.5%
Net Margin6.9%
Last Earnings Update31 May 2024

Recent past performance updates

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Dec 18
Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Recent updates

Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings

Aug 22
Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings

Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue

Aug 21
Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Jul 14
Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

May 09
Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28
Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Jan 24
Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Dec 18
Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Jul 29
Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10
Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26
Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27
Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10
Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16
Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22
Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Revenue & Expenses Breakdown

How Cannara Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:LOVE Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 May 24775181
29 Feb 24736171
30 Nov 23669151
31 Aug 23577141
31 May 23515131
28 Feb 23453111
30 Nov 22403111
31 Aug 22362101
31 May 22301101
28 Feb 2227191
30 Nov 2122182
31 Aug 2117-272
31 May 2111-772
28 Feb 215-1173
30 Nov 203-1383
31 Aug 203-1293
31 May 203-12112
29 Feb 202-12121
30 Nov 192-13110
31 Aug 192-12110
31 Aug 181-440

Quality Earnings: LOVE has a large one-off gain of CA$2.3M impacting its last 12 months of financial results to 31st May, 2024.

Growing Profit Margin: LOVE's current net profit margins (6.9%) are lower than last year (9.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LOVE has become profitable over the past 5 years, growing earnings by 74.5% per year.

Accelerating Growth: LOVE's earnings growth over the past year (9.2%) is below its 5-year average (74.5% per year).

Earnings vs Industry: LOVE earnings growth over the past year (9.2%) exceeded the Personal Products industry 4.7%.


Return on Equity

High ROE: LOVE's Return on Equity (6.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies